Literature DB >> 23372151

Peripheral neuropathy in multiple myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVD) therapy.

Peter M Voorhees, Jacob Laubach, Kenneth C Anderson, Paul G Richardson.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 23372151      PMCID： PMC5318671          DOI： 10.1182/blood-2012-11-465765

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  7 in total

1.  A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.

Authors:  Andrzej J Jakubowiak; Dominik Dytfeld; Kent A Griffith; Daniel Lebovic; David H Vesole; Sundar Jagannath; Ammar Al-Zoubi; Tara Anderson; Brian Nordgren; Kristen Detweiler-Short; Keith Stockerl-Goldstein; Asra Ahmed; Terri Jobkar; Diane E Durecki; Kathryn McDonnell; Melissa Mietzel; Daniel Couriel; Mark Kaminski; Ravi Vij
Journal:  Blood       Date:  2012-06-04       Impact factor: 22.113

2.  Treating myeloma: the future is already here!

Authors:  Ola Landgren; Neha Korde
Journal:  Blood       Date:  2012-08-30       Impact factor: 22.113

3.  Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.

Authors:  Paul G Richardson; Edie Weller; Sagar Lonial; Andrzej J Jakubowiak; Sundar Jagannath; Noopur S Raje; David E Avigan; Wanling Xie; Irene M Ghobrial; Robert L Schlossman; Amitabha Mazumder; Nikhil C Munshi; David H Vesole; Robin Joyce; Jonathan L Kaufman; Deborah Doss; Diane L Warren; Laura E Lunde; Sarah Kaster; Carol Delaney; Teru Hideshima; Constantine S Mitsiades; Robert Knight; Dixie-Lee Esseltine; Kenneth C Anderson
Journal:  Blood       Date:  2010-04-12       Impact factor: 22.113

4.  Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events.

Authors:  Shirin Arastu-Kapur; Janet L Anderl; Marianne Kraus; Francesco Parlati; Kevin D Shenk; Susan J Lee; Tony Muchamuel; Mark K Bennett; Christoph Driessen; Andrew J Ball; Christopher J Kirk
Journal:  Clin Cancer Res       Date:  2011-03-01       Impact factor: 12.531

Review 5.  Management of treatment-emergent peripheral neuropathy in multiple myeloma.

Authors:  P G Richardson; M Delforge; M Beksac; P Wen; J L Jongen; O Sezer; E Terpos; N Munshi; A Palumbo; S V Rajkumar; J L Harousseau; P Moreau; H Avet-Loiseau; J H Lee; M Cavo; G Merlini; P Voorhees; W J Chng; A Mazumder; S Usmani; H Einsele; R Comenzo; R Orlowski; D Vesole; J J Lahuerta; R Niesvizky; D Siegel; M-V Mateos; M Dimopoulos; S Lonial; S Jagannath; J Bladé; J San Miguel; G Morgan; K C Anderson; B G M Durie; P Sonneveld
Journal:  Leukemia       Date:  2011-12-23       Impact factor: 11.528

6.  Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.

Authors:  Philippe Moreau; Halyna Pylypenko; Sebastian Grosicki; Ievgenii Karamanesht; Xavier Leleu; Maria Grishunina; Grigoriy Rekhtman; Zvenyslava Masliak; Tadeusz Robak; Anna Shubina; Bertrand Arnulf; Martin Kropff; James Cavet; Dixie-Lee Esseltine; Huaibao Feng; Suzette Girgis; Helgi van de Velde; William Deraedt; Jean-Luc Harousseau
Journal:  Lancet Oncol       Date:  2011-04-18       Impact factor: 41.316

7.  Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.

Authors:  Paul G Richardson; Wanling Xie; Constantine Mitsiades; Asher A Chanan-Khan; Sagar Lonial; Hani Hassoun; David E Avigan; Anne Louise Oaklander; David J Kuter; Patrick Y Wen; Santosh Kesari; Hannah R Briemberg; Robert L Schlossman; Nikhil C Munshi; L Thompson Heffner; Deborah Doss; Dixie-Lee Esseltine; Edie Weller; Kenneth C Anderson; Anthony A Amato
Journal:  J Clin Oncol       Date:  2009-06-15       Impact factor: 44.544
  7 in total
  6 in total

1.  Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro.

Authors:  Chris Mahony; Lynda Erskine; Jennifer Niven; Nigel H Greig; William Douglas Figg; Neil Vargesson
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-15       Impact factor: 11.205

Review 2.  The double-edged sword: Neurotoxicity of chemotherapy.

Authors:  Rajiv S Magge; Lisa M DeAngelis
Journal:  Blood Rev       Date:  2014-09-28       Impact factor: 8.250

3.  Diagnostic utility of Sudoscan for detecting bortezomib-induced painful neuropathy: a study on 18 patients with multiple myeloma.

Authors:  Alessandro Allegra; Vincenzo Rizzo; Vanessa Innao; Angela Alibrandi; Anna Mazzeo; Rossana Leanza; Carmen Terranova; Luca Gentile; Paolo Girlanda; Andrea Gaetano Allegra; Andrea Alonci; Caterina Musolino
Journal:  Arch Med Sci       Date:  2021-01-11       Impact factor: 3.707

Review 4.  Common Adverse Effects of Novel Therapies for Multiple Myeloma (MM) and Their Management Strategies.

Authors:  Kristen B McCullough; Miriam A Hobbs; Jithma P Abeykoon; Prashant Kapoor
Journal:  Curr Hematol Malig Rep       Date:  2018-04       Impact factor: 3.952

5.  Measuring symptoms as a critical component of drug development and evaluation in hematological diseases.

Authors:  Loretta A Williams; Emre Yucel; Jorge E Cortes; Charles S Cleeland
Journal:  Clin Investig (Lond)       Date:  2013-12-01

6.  Repurposing Pomalidomide as a Neuroprotective Drug: Efficacy in an Alpha-Synuclein-Based Model of Parkinson's Disease.

Authors:  Maria Francesca Palmas; Anna Ena; Chiara Burgaletto; Maria Antonietta Casu; Giuseppina Cantarella; Ezio Carboni; Michela Etzi; Alfonso De Simone; Giuliana Fusco; Maria Cristina Cardia; Francesco Lai; Luca Picci; David Tweedie; Michael T Scerba; Valentina Coroneo; Renato Bernardini; Nigel H Greig; Augusta Pisanu; Anna R Carta
Journal:  Neurotherapeutics       Date:  2022-01-24       Impact factor: 6.088
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.